Drugs / epoetinum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00676234 | May 2008 → Jun 2009 | acute kidney injury | University Hospital, Geneva | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epoetinum | “Drug: epoetinum” NCT00676234 ↗ |
| Known as | epoietinum-alpha | “The brand name is EPREX® which is epoietinum-alpha in sterile buffered solution for i.v. or s.c. injection.” NCT00676234 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human erythropoietin” NCT00676234 ↗ |
| Route | Intravenous | “administered by the i.v. route” NCT00676234 ↗ |